COMPANY PROFILE

RemeGen / 荣昌生物

Explore full profile

Yantai STAR-listed commercial ADC and mAb biologics OEM (STAR 688331)

Yantai, ChinaFounded 2008Biotech & Life Sciences

Valuation $2.5–5B Last recorded · 2020

Revenue $100–500M Latest reported FY

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About RemeGen / 荣昌生物

Yantai STAR/HK-listed commercial biologics OEM (RemeGen / 荣昌生物; STAR 688331) — ADCs and monoclonal antibodies spanning autoimmune, oncology and ophthalmic indications (telitacicept / disitamab vedotin class) — mid-size China ADC leftover beyond Mon MabPlex CDMO DNR / Duality clinical-stage softer / Bio-Thera employees-only thinner. The company discovers, develops, manufactures and commercializes differentiated biologic drugs for unmet medical needs in China and via partners.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2008
Headquarters: Yantai, China
Employees: 18
Open positions: 74
Dealroom signal: 26.3/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company
Capital deployed: —
Preferred round: Unknown
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SECONDARY✓Other financing	Apr 2022	$410M	—	Undisclosed	↗
IPO✓Exit	Nov 2020	$515M	$4.3B	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

RemeGen / 荣昌生物 website traffic

Latest recorded traffic for RemeGen / 荣昌生物 is 550 monthly website visits, down 73.8% over the last three months. RemeGen / 荣昌生物's team grew 0% over the past year.

Latest monthly visits550 3-month web change-73.8% 1-year team growth0%

Monthly website visitsFeb 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

RPM-(Guangzhou, Guangdong, China · Sales · Sep 5, 2026 ITBP (MJ002128)Beijing, Beijing, China · Other · Sep 4, 2026 -Beijing, Beijing, China · Sales · Aug 31, 2026 -Hangzhou, Zhejiang, China · Sales · Aug 30, 2026 sfe/Yantai, Shandong, China · Other · Aug 30, 2026 () (MJ002131)Yantai, Shandong, China · Other · Aug 30, 2026 (MJ002129)Yantai, Shandong, China · Other · Aug 28, 2026 AI (MJ002127)Yantai, Shandong, China · Data Science & Engineering · Aug 28, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MBMediphage BioceuticalsCures for chronic diseases	Toronto, Canada	Operational	6	$3.8M	$800K
MTMonopar TherapeuticsEmerging biopharmaceutical company focused on developing orphan oncology compounds	Lake Forest, United States	Operational
XPX4 PharmaceuticalsClinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment	Cambridge, United States	Operational
LALakewood AmedexLakewood-Amedex Inc, a development-stage biopharmaceutical company,	Jacksonville, United States	Operational
SSSequoia SciencesPharmaceutical company discovering and developing new medicines for the treatment of bacterial infections and cancers	St. Louis, United States	Operational
CACavionClinical stage pharmaceutical company committed to providing patients with therapies	Charlottesville, United States	Acquired
GBGossamer BioFocused on the discovery and development of novel and differentiated therapeutic products	San Diego, United States	Operational
MIMironidSmall molecule therapeutics for hereditary kidney disease	Glasgow, United Kingdom	Operational